Blood Group M antigen Inhibitors
Blood group M antigen inhibitors are a class of chemical compounds that specifically target the M antigen, one of the antigens in the MNS blood group system. The M antigen is found on the surface of red blood cells and is associated with the glycophorin A protein, a sialoglycoprotein that spans the red blood cell membrane. The M antigen, along with its counterpart N antigen, differs based on the amino acids at specific positions on the glycophorin A protein. The M antigen is characterized by the presence of serine and glycine at positions 1 and 5, respectively. Blood group M antigen inhibitors work by disrupting the molecular interactions or synthesis of these specific structures, affecting the presentation of the M antigen on the red blood cell surface. These inhibitors are essential for studying the molecular biology of blood group antigens and understanding the processes that regulate cell surface glycoprotein expression.
Blood group M antigen inhibitors can function by targeting the glycoprotein itself or the processes that lead to its modification and presentation on the cell membrane. These inhibitors may bind to the glycophorin A protein, preventing it from adopting its normal structure or interacting with other molecules in the cellular environment. Additionally, some inhibitors might interfere with the post-translational modifications of the protein, such as glycosylation, which is important for antigen recognition. Researchers use blood group M antigen inhibitors to investigate the specific biochemical pathways that control the expression of glycophorin A and the factors that influence the antigenic properties of red blood cells. By blocking or modifying the activity of the M antigen, scientists gain insights into the broader role of glycoproteins in red blood cell function, cell signaling, and molecular recognition in hematology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor could hypothetically induce global hypomethylation, leading to the downregulation of the GYPA gene responsible for Blood Group M antigen expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
As a histone deacetylase inhibitor, Trichostatin A may cause chromatin to remain in a more open state, potentially decreasing transcriptional activity of certain genes, including the one encoding the Blood Group M antigen. | ||||||
Anacardic Acid | 16611-84-0 | sc-202463 sc-202463A | 5 mg 25 mg | $102.00 $204.00 | 13 | |
The inhibition of histone acetyltransferases by Anacardic Acid might lead to altered histone modifications and could result in the decreased expression of the gene coding for the Blood Group M antigen. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
By intercalating into DNA, Actinomycin D can inhibit transcription initiation and elongation, which would result in a decrease in the synthesis of mRNA for the Blood Group M antigen. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
This ribonucleotide reductase inhibitor could reduce the pool of deoxyribonucleotides available for DNA synthesis, leading to reduced replication and expression of genes including those coding for the Blood Group M antigen. | ||||||
Topotecan | 123948-87-8 | sc-338718 | 100 mg | $582.00 | ||
As a topoisomerase inhibitor, Topotecan could disrupt the normal unwinding and rewinding of DNA strands, thereby leading to a halt in transcription and subsequent decrease in Blood Group M antigen production. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
This compound binds to the eukaryotic ribosome, particularly the 60S subunit, leading to an inhibition of translational elongation and a subsequent reduction in overall protein synthesis, including that of Blood Group M antigen. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibiting the PI3K/Akt/mTOR pathway with LY 294002 could lead to the downregulation of proteins that are under control of this signaling pathway, potentially including a decrease in the expression of the Blood Group M antigen. | ||||||
1-β-D-Arabinofuranosylcytosine | 147-94-4 | sc-201628 sc-201628A sc-201628B sc-201628C sc-201628D | 1 g 5 g 25 g 100 g 250 g | $150.00 $263.00 $518.00 $731.00 $1461.00 | 1 | |
1-β-D-Arabinofuranosylcytosine acts as a nucleoside analog, disrupting DNA synthesis. By inhibiting DNA polymerase, it could lead to a decrease in the proliferation of cells expressing the Blood Group M antigen. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
This compound inhibits the spliceosome, which is crucial for the processing of pre-mRNA. Disruption of splicing could lead to improper mRNA maturation and a subsequent decrease in the levels of the Blood Group M antigen. | ||||||